Recent Blog Articles

Harvard Health Blog

A monthly shot for opioid addiction: An option for some

Vivitrol-blog-04-01-16
April 01, 2016

Disclaimer:

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Comments

ウィリアムキャンベルユーユーカ
May 10, 2016

ハーバード大学総長です。東京都武蔵野市境南町1-5-2コーポリリーにいます、トッパン・フォームズ株式会社日野センター総務本部に、どちらかにハーバード大学総長救援チームを寄越してください。よろしくお願い致します。

Livescan Noc
April 02, 2016

It will help a lot of people

Jennifer Viera
April 01, 2016

This week a study was published today in The New England Journal of Medicine. It showed that in a randomized controlled clinical trial, Vivitrol significantly prevented relapse to opioid dependence in men previously substance-dependent and involved with the criminal justice system. Here’s a link to the study. Full text is free.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505409?query=featured_home#t=articleTop

Wynne Armand
April 04, 2016

Thank you for your comment regarding this new study publication. The results are encouraging: long-acting naltrexone was a more effective treatment option in this patient population when given in addition to the usual community counseling programs (21% lower relapse rate during the 6-month trial). It is also encouraging that there were fewer overdoses both during and after completion of the 6-month naltrexone treatment. Unfortunately, the benefit of relapse prevention in this naltrexone study group was only present during the 6 months of treatment with injections, as the rate of opioid use was similar in both groups at the 12-month and 18-month follow-ups.

Commenting has been closed for this post.